AGENUS INC (AGEN)
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business